Educating Hemodialysis Patients on Phosphorus Binders in Emergencies
This project addresses a critical gap in emergency preparedness for hemodialysis-dependent patients by designing and implementing a structured education program on the use of phosphorus binders — specifically Renagel (sevelamer hydrochloride) — when dialysis services are unavailable during power outages or natural disasters. Using Kotter's Eight-Step Change Model as its theoretical framework, the project trained clinical staff to educate patients at a dialysis facility, with the goal of having 80% of 99 patients trained by August 30, 2015. The paper reviews the clinical rationale for phosphorus binders, summarizes supporting literature, outlines a PICO statement, presents a cost-benefit analysis, and provides manufacturer guidance on Renagel dosing, precautions, and side effects.
- Introduction and Project Overview: Project aim, scope, and AIM statement
- Clinical Rationale and Literature Review: Evidence supporting phosphorus binders over alternatives
- Methodology: Kotter's Eight-Step Change Model: Change theory applied to education initiative
- Implementation Plan, Data Collection, and Predictions: Steps, barriers, and outcome measurement strategy
- PICO Statement and Expected Outcomes: Clinical question framed with PICO structure
- Budget, Benefits, and SWOT Analysis: Cost breakdown, patient benefits, and SWOT
- Renagel (Sevelamer Hydrochloride): Clinical Guidance and Precautions: Dosing, side effects, and drug precautions
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- The paper grounds a practical clinical education initiative in an established change management theory (Kotter's Eight-Step Model), giving the project both structural rigor and a recognized scholarly framework.
- It integrates a PICO statement, a cost-benefit budget, and a SWOT analysis, demonstrating systematic clinical project planning appropriate for a CNL-level capstone.
- The literature review draws on peer-reviewed nephrology and pharmacology sources to justify the clinical choice of sevelamer over earlier aluminum- and calcium-based binders, showing evidence-based reasoning.
Key academic technique demonstrated
The paper exemplifies translational research application — it takes existing clinical evidence on phosphorus binder efficacy and translates it into a concrete, time-bound education intervention with measurable outcomes. The use of a PICO framework to structure the research question is a strong example of evidence-based practice methodology commonly expected at the graduate nursing level.
Structure breakdown
The paper opens with an AIM statement and project overview, then moves to clinical rationale supported by a literature review. Methodology is presented through Kotter's eight phases applied step-by-step to the project context. An implementation plan with data collection strategy follows. The PICO statement formalizes the clinical question, and the paper closes with budget, benefits, a SWOT analysis, and a detailed pharmaceutical appendix on Renagel. This progression from problem identification through evidence, theory, planning, and evaluation mirrors the structure of a formal clinical improvement project.
Introduction and Project Overview
The clinical leadership competency framing this project requires effective transformational leadership practices that can motivate all stakeholders to become educated concerning the use of phosphorus binders in lieu of dialysis during emergencies (Cook, 2004). The patient population of interest is hemodialysis-dependent patients. The intervention is education and training on the use of phosphorus binders as a substitute for hemodialysis treatment during power outages or other emergencies, with the outcome measure being a successful return demonstration of how and when to use phosphorus binders. The timeline goal was to have 80% of 99 patients educated by August 30, 2015.
This project involves training selected clinical staff members to provide educational support services to hemodialysis-dependent patients concerning the use of a phosphorus-binding drug, Renagel, to prepare them for emergency situations when dialysis services are unavailable.
AIM Statement: By August 15, 2015, 80% of hemodialysis-dependent patients will be educated and prepared to use phosphorus binders in lieu of hemodialysis treatment during power outages or other emergency situations.
Clinical Rationale and Literature Review
The use of phosphorus binders for hemodialysis patients is not new. The original binders were aluminum-containing compounds that were shown to be highly effective in lowering phosphorus levels; however, these original phosphorus binders resulted in multisystem toxicity and their use was therefore largely discontinued (Beyzarov, 2009). An alternative was found in calcium-containing binders, which were regarded as safer, but this intervention was found to cause accumulation of calcifications in multiple tissues, resulting in increased patient mortality — especially among patients with advanced-stage chronic kidney disease — and their use was also largely discontinued (Beyzarov, 2009).
Since its approval, the use of non-calcium-, non-aluminum-containing phosphorus binders gained increased acceptance by the healthcare community following the publication of results in Kidney International showing that patients treated with sevelamer experienced significantly lower mortality rates related to the control of coronary artery calcifications compared with patients treated with calcium-based phosphate binders (Beyzarov, 2009). These drugs represent potentially life-saving alternative treatments for hemodialysis-dependent patients during emergency situations when power is lost or dialysis equipment is otherwise inoperable (Lemieux & Chamberlin, 2015).
A study by Sheikh, Maguire, Emmett et al. (2009) reports that phosphorus binding can assume various forms, including a chemical reaction between dietary phosphorus and the cation of the binder compound, adsorption of phosphorus ions on the surface of binder particles, or a combination of both processes. Until fairly recently, aluminum-containing antacids were used as phosphorus binders, but studies demonstrated that long-term use of aluminum compounds by patients with chronic renal failure is associated with a risk of serious aluminum toxicity, prompting a search for safer alternatives (Sheikh et al., 2009).
Emmett (2004) argues that the optimal approach for phosphorus maintenance in hemodialysis-dependent patients is to balance the net amount of phosphorus absorbed from the gastrointestinal tract to correspond to decreased kidney function. While chronic dialysis therapy can achieve this balance, it is very challenging to reduce dietary phosphorus to appropriate levels, and a wide range of phosphorus binders have been used for this purpose (Emmett, 2004).
More recently, non-calcium-, non-aluminum-containing phosphorus binders have been shown to be a considerable improvement over these two earlier interventions (Beyzarov, 2009). As Beyzarov reports, "The new binders were not systemically absorbed and provided phosphorus control without concerns of calcium or metal accumulation" (2009, p. 9). Kalantar-Zadeh (2013) notes that chronic kidney disease has been linked to an increased risk of cardiovascular disease and mortality associated with traditional cardiovascular risk factors such as diabetes and hypertension. Research also indicates a significant link between elevated serum phosphorus and mortality in dialysis patients, with hyperphosphatemia representing the highest risk of death in hemodialysis patients (Kalantar-Zadeh, 2013). Phosphorus binders therefore represent a valuable tool in controlling hyperphosphatemia (Kalantar-Zadeh, 2013).
Isakova et al. (2009) evaluated a prospective cohort study of 10,044 incident hemodialysis patients using Cox proportional hazards analyses to analyze one-year all-cause mortality among patients receiving or not receiving phosphorus binders. These researchers compared patients beginning treatment with phosphorus binders during the first 90-day period following initiation of hemodialysis with patients who were left untreated during the same period (Isakova et al., 2009). They found that treatment with phosphorus binders is independently associated with improved survival among incident hemodialysis patients and concluded that phosphorus binders represent a valuable tool in treating patients with chronic kidney disease.
De Francisco (2008) argues that while numerous researchers have evaluated the efficacy of phosphorus binders in decreasing serum phosphate levels and uniformly found the intervention effective, there remains a paucity of research concerning its efficacy compared to other phosphorus-chelating agents. The few available studies indicate that phosphorus binders and calcium compounds are equally efficacious after one year of treatment; however, phosphorus binders demonstrated additional beneficial effects, including a lower incidence of hypercalcemia, a minimal decrease in serum calcium levels, lower incidence of low PTH levels, lower LDL cholesterol, and a significantly lower percentage in the mean absolute score of calcium within the coronary arteries and aorta (de Francisco, 2008). Phosphorus binders also decreased C-reactive protein values compared to calcium compounds (de Francisco, 2008). It should be noted, however, that phosphorus binders should not be used for patients with chronic kidney disease who are not actively receiving hemodialysis, because the drug can induce metabolic acidosis (de Francisco, 2008).
Create your account
Always verify citation format against your institution’s current style guide requirements.